TIDMAKR
Akers Biosciences, Inc.
16 June 2015
For immediate release: 16 June 2015
Akers Biosciences Updates on New Rapid Breath Ketone and
Oxidative Stress Tests for Health and Wellness Industry
Pre-production Product Reservations Received
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a medical device company focused on
reducing the cost of healthcare through faster, easier diagnostics,
is pleased to provide an update on the progress of the Company's
Wellness division following the introduction in May of two new
breath tests at the World Congress on Anti--Aging Medicine (the
"Congress").
"The response to the Akers Wellness products has been
overwhelmingly positive," said Raymond F. Akers, Jr. PhD,
Co--founder and Executive Chairman. "Participation at the Congress
was designed to raise awareness of these new tools to assist in
weight loss and anti-aging programs, and to gather customer
feedback, but in fact it resulted in several hundred reservations
for products once commercial production begins in Q3," continued
Dr. Akers.
The Wellness products, known as BreathScan OxiCheck(TM)
("OxiChek(TM)") and BreathScan KetoChek(TM) ("KetoChek(TM)"),
together with the bluetooth-enabled reading device, BreathScan
Lync(TM) - which synchs via an app on any mobile device - will
enable consumers to monitor trends in critical metabolic processes.
In addition, suppliers of nutritional supplements and diet plans,
and health coaches in fitness centers, will be able to more
effectively monitor and adjust the progress of their clients.
OxiChek(TM) is Akers' second generation disposable breath test
to rapidly determine levels of oxidative stress (free radicals) in
the body and, to the Company's knowledge, is the only device of its
kind on the market. Frequent use of OxiChek(TM) may help consumers
comply with and adhere to their regimen of nutritional
supplementation for management of oxidative stress, which is
implicated in many diseases, including cardiac, cancer and
arthritic diseases.
KetoChek(TM) is the second generation of Akers Bio's disposable
breath-based diagnostic device that rapidly determines if the
subject is in the optimal fat-burning state for weight loss, known
as ketosis. Achieving a state of ketosis is a goal of many
individuals following low carbohydrate diets. KetoChek(TM) is a
simple, non-invasive process to identify, track and monitor ketosis
for individuals interested in maximizing weight loss, or
fat-burning metabolism for endurance athletics. To the Company's
knowledge, Akers Bio's rapid ketone tests are the only disposable,
breath-based ketone detection devices on the market.
Since the Congress in May, Akers Bio has established several
strategic partnerships intended to advance the commercialization of
these products. This includes a partnership with SPRIM, an
international marketing consulting firm, to develop marketing
strategies and implement a targeted sales effort. With SPRIM, the
Company has broadened its initial target market of multilevel
marketing firms to now include fitness centers and diet plans, as
well as the anti-aging, functional and integrative medicine
sectors.
In addition, the Company has partnered with FirstApp, a software
company which has developed mobile apps for leading international
pharmaceutical firms. Akers Bio is working with FirstApp to develop
iOS (Apple) and Android apps to work in tandem with the
KetoChek(TM) and OxiChek(TM) breath test devices in a useful and
consumer-friendly format. It is intended that the app will have the
additional capability to gather data to link lifestyle changes with
the use of Akers Bio's products.
"We believe that the response to the Akers Wellness product
introduction sends a clear message that there is a strong demand
for efficiently delivered personalized health information," added
Dr. Akers. "KetoChek(TM) and OxiChek(TM) will address this growing
demand in the considerable weight loss and anti-aging markets."
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMGMVFVGGKZM
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024